Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
CALY-ZM is a combination nutritional supplement developed and marketed by Bennet Pharmaceuticals. It contains calcium citrate, cholecalciferol (vitamin D3), magnesium, and zinc. This formulation is primarily indicated for the management of calcium deficiency and the prevention or treatment of bone-related conditions such as osteoporosis, osteomalacia, and rickets. Calcium citrate serves as a source of elemental calcium necessary for bone formation and maintenance. Cholecalciferol facilitates the intestinal absorption of calcium and phosphate by acting as an agonist at the vitamin D receptor. Magnesium and zinc are essential minerals that support bone mineralization and enzymatic processes involved in bone metabolism.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on calcium citrate + cholecalciferol + magnesium + zinc.